GPELFGlobal Programme to Eliminate Lymphatic Filariasis
References in periodicals archive ?
This study assessed the effect of disability limitation program which is one of the strategies of GPELF.
Global programme to eliminate lymphatic filariasis (GPELF) and global alliance to eliminate lymphatic filari asis (GAELF) estimated that currently, 81 countries are considered endemic for LF, and about 1.34 billion, persons are at the risk of infection.
In 2000, GPELF established two major strategies to achieve the goal of eliminating LF as a public health problem by 2020: 1) interrupting transmission through annual MDAs and 2) reducing the burden of disease through morbidity management (5).
Background & objectives: Albendazole, a commonly used anthelminthic drug that targets the polymerization of [alpha]- and [beta]-tubulin dimer is currently co-administered with the antifilarial drug, diethylcarbamazine citrate (DEC) in the ongoing Global Programme for Elimination of Lymphatic Filariasis (GPELF).
Kar, Director, RMRC, Bhabaneswar, participated in the meeting on Resolving Critical Challenges in the GPELF at Geneva (January 9-10, 2008).
Global Programme to Eliminate Lymphatic Filariasis (GPELF) is a rapidly growing worldwide public health programme launched in 2000 with the goal of eliminating the disease as a public health problem by 2020.